(Midi does not prescribe this or other unapproved peptides.) What the science says: Preliminary studies (on Covid patients) have found that TA-1 seems to help regulate the immune system and restore immune function
Phase 3 trials extending to 72 weeks will provide more complete data on ultimate efficacy
Combination Therapy : it can also be used in combination with other diabetes specifics to enhance their effectiveness
According to CMS, qualification requires a BMI of: BMI 35 with no additional clinical condition required , or BMI 30 with at least one of : heart failure, uncontrolled hypertension, or chronic kidney disease, or BMI 27 with at least one of : pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Vogt is responsive, professional and thoughtful in his treatment